Stock Events

Stock Events

VBI Vaccines 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Dec 12
€17.02
Apr 12
€11.43
Jan 4
€5.69
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a direct competitor in the development of vaccines, including those for infectious diseases, similar to VBI Vaccines' focus.
Moderna
MRNA
Mkt Cap27.09B
Moderna is a leader in mRNA vaccine technology, competing in the same space as VBI Vaccines with its development of vaccines for infectious diseases.
BioNTech
BNTX
Mkt Cap23.14B
BioNTech competes with VBI Vaccines in the development of vaccines for infectious diseases, utilizing mRNA technology.
Pfizer
PFE
Mkt Cap137.76B
Pfizer, in collaboration with BioNTech, has developed mRNA vaccines, making it a competitor in the infectious disease vaccine market.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines for infectious diseases, competing with VBI Vaccines.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline is a large pharmaceutical company with a significant vaccine portfolio, making it a competitor in the vaccine market.
Sanofi
SNY
Mkt Cap104.13B
Sanofi is involved in the development and marketing of vaccines for various diseases, competing with VBI Vaccines.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca has developed COVID-19 vaccines among others, positioning it as a competitor in the vaccine market.
Inovio Pharmaceuticals
INO
Mkt Cap97.08M
Inovio Pharmaceuticals focuses on DNA vaccines for infectious diseases and cancer, competing in the vaccine development space.

About

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Show more...
CEO
Mr. Jeffery R. Baxter FCMA
Employees
131
Country
Canada
ISIN
CA91822J1030

Listings

STU
DE
LO91.STU

0 Comments

Share your thoughts

FAQ

What is VBI Vaccines stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange VBI Vaccines stocks are traded under the ticker LO91.STU.
Does VBI Vaccines pay dividends?▼
Yes, LO91.STU dividends are paid annual. The last dividend per share was 17.02 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does VBI Vaccines have?▼
As of July 25, 2026, the company has 131 employees.
In which sector is VBI Vaccines located?▼
VBI Vaccines operates in the Health & Wellness sector.
When did VBI Vaccines complete a stock split?▼
The last stock split for VBI Vaccines was on April 12, 2023 with a ratio of 1:30.
Where is VBI Vaccines headquartered?▼
VBI Vaccines is headquartered in Cambridge, Canada.